These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32859216)

  • 1. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study.
    Zheng Y; Wu J; Ding C; Xu K; Yang S; Li L
    Virol J; 2020 Aug; 17(1):132. PubMed ID: 32859216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of comorbid type 2 diabetes mellitus on the disease burden of chronic hepatitis B virus infection and its complications in China from 2006 to 2030: a modeling study.
    Xie J; Wang X; Wang X; Li J; Jie Y; Hao Y; Gu J
    Glob Health Res Policy; 2024 Jan; 9(1):5. PubMed ID: 38246986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
    Idris BI; Brosa M; Richardus JH; Esteban R; Schalm SW; Buti M
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):320-6. PubMed ID: 18334876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of Markov models for economics evaluation of strategies on hepatitis B vaccination and population-based antiviral treatment in China].
    Yang PC; Zhang SX; Sun PP; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):845-851. PubMed ID: 28738454
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
    Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort.
    Zhu L; Zhai X; Wang Q; Jiang J; Peng H; Song C; Ge Z; Qian J; Zhou M; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhu F
    J Viral Hepat; 2018 Dec; 25(12):1588-1598. PubMed ID: 30112835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.
    Zhang S; Wang C; Liu B; Lu QB; Shang J; Zhou Y; Jia J; Xu X; Rao H; Han B; Zhao T; Chen L; Xie M; Cui J; Du J; Zeng J; Huang N; Liu Y; Zhang L; Zhuang H; Cui F
    Lancet Reg Health West Pac; 2023 Jun; 35():100738. PubMed ID: 37424693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current and future burden of hepatitis B in Switzerland: a modelling study.
    Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
    Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
    Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
    J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model.
    Zu J; Li M; Zhuang G; Liang P; Cui F; Wang F; Zheng H; Liang X
    Medicine (Baltimore); 2018 Apr; 97(16):e0484. PubMed ID: 29668627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis B in Asia-new insights from the past decade.
    Chan HL; Jia J
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():131-7. PubMed ID: 21199524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of acute hepatitis E super-infections on chronic hepatitis B.
    Chen C; Zhang SY; Zhang DD; Li XY; Zhang YL; Li WX; Yan JJ; Wang M; Xun JN; Lu C; Ling Y; Huang YX; Chen L
    World J Gastroenterol; 2016 Dec; 22(47):10388-10397. PubMed ID: 28058019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
    Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
    J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
    Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
    J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to control highly endemic hepatitis B in Asia.
    Shan S; Cui F; Jia J
    Liver Int; 2018 Feb; 38 Suppl 1():122-125. PubMed ID: 29427490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.